Progress towards antibiotic use targets in eight high-income countries

Bryony Simmons, Koya Ariyoshi, Norio Ohmagari, Celine Pulcini, Benedikt Huttner, Sumanth Gandra, Giovanni Satta, Lorenzo Moja, Michael Sharland, Nicola Magrini, Marisa Miraldo & Graham Cooke

Objective To compare antibiotic sales in eight high-income countries using the 2019 World Health Organization (WHO) Access, Watch and Reserve (AWaRe) classification and the target of 60% consumption of Access category antibiotics.

Methods We analysed data from a commercial database of sales of systemic antibiotics in France, Germany, Italy, Japan, Spain, Switzerland, United Kingdom of Great Britain and Northern Ireland, and United States of America over the years 2013–2018. We classified antibiotics according to the 2019 AWaRe categories: Access, Watch, Reserve and Not Recommended. We measured antibiotic sales per capita in standard units (SU) per capita and calculated Access group sales as a percentage of total antibiotic sales.

Findings In 2018, per capita antibiotic sales ranged from 7.4 SU (Switzerland) to 20.0 SU (France); median sales of Access group antibiotics were 10.9 SU per capita (range: 3.5–15.0). Per capita sales declined moderately over 2013–2018. The median percentage of Access group antibiotics was 68% (range: 22–77%); the Access group proportion increased in most countries between 2013 and 2018. Five countries exceeded the 60% target; two countries narrowly missed it (>55% in Germany and Italy). Sales of Access antibiotics in Japan were low (22%), driven by relatively high sales of oral cephalosporins and macrolides.

Conclusion We have identified changes to prescribing that could allow countries to achieve the WHO target. The 60% Access group target provides a framework to inform national antibiotic policies and could be complemented by absolute measures and more ambitious values in specific settings.

Introduction Antimicrobial resistance is a major threat to global health, endangering the ability to prevent and manage many common infectious diseases. High rates of use and misuse of antibiotics have contributed to selection pressures on drug-resistant strains of common pathogens, leading to a shift towards more expensive and broad-spectrum antibiotics. In 2015, the World Health Assembly adopted a Global Action Plan on Antimicrobial Resistance, calling for optimization of the use of antimicrobials. Key to optimization is to promote access to appropriate antibiotics while avoiding excess use.

The Access, Watch and Reserve (AWaRe) categorization is a tool introduced by the World Health Organization (WHO) to encourage antibiotic stewardship and to combat antimicrobial resistance. The categorization was first introduced in the 2017 WHO essential medicines list, in which key antibiotics were classified into three categories – Access, Watch and Reserve – according to their therapeutic and resistance profile. Access group antibiotics are defined as priority treatments recommended as first- and second-choice options for common infections that should be available and affordable in all countries. The Watch group contains broad-spectrum antibiotics with a higher resistance potential that are recommended for a specific, limited number of indications. The Reserve group includes antibiotics for multidrug-resistant infections that should be treated as last-resort options in highly specific patients and settings. Recognizing the role of the AWaRe as a policy tool, the WHO essential medicines list expert committee updated the classification in 2019 to categorize additional antibiotics into the three groups and to add a new category: Not Recommended. To reduce the use of Watch and Reserve group antibiotics, the WHO Thirteenth General Programme of Work 2019–2023 has adopted the following target to be reached by 2023: at least 60% of national antibiotic consumption should be from the Access group. Adoption of this target at the national level should help to inform and galvanize action and can be used to monitor progress, allowing for comparison of antibiotic stewardship efforts.

Global antibiotic consumption and prescribing behaviours have been described in studies in different countries, with variations in study years, data sources, breadth of analysis and patient populations (for example, paediatrics, hospital setting or overall population). In relation to AWaRe, antibiotic consumption by children has been measured against the 2017 AWaRe classification, with several countries falling short of the target of 60% use of Access group antibiotics. Similar findings have been observed in general population studies, including the WHO report on surveillance of antibiotic consumption and a recent multi-country analysis, both using data up to 2015. We aimed to add to this body of work by using sales data to assess patterns of antibiotic sales according to the 2019 AWaRe categories in eight high-income countries over the years 2013–2018. The objectives were to inform policy dis-
Method

Study design

To obtain indication of antibiotic consumption patterns, we used aggregate sales data as proxy. We analysed wholesale antibiotic sales data for 2013–2018 from eight countries to determine patterns of sales with reference to the 2019 WHO AWaRe classification. The countries included were: France, Germany, Italy, Japan, Spain, Switzerland, United Kingdom of Great Britain and Northern Ireland, and United States of America (USA). We chose the countries and years of observation based on the availability of data. The included countries are representative of high-income countries with large pharmaceutical markets, in regions with varying antibiotic resistance profiles and health-care contexts.

Data sources

We used the IQVIA multinational integrated data analysis system database (IQVIA Inc., Durham, USA) to identify antibiotic sales. This commercial database tracks pharmaceutical sales by using national sales audits of manufacturers and wholesalers, through retail and non-retail channels. IQVIA standardizes the data to ensure they are nationally representative and to allow for comparability across markets. Table 1 shows the data sources and coverage of the database for our sample. We extracted national quarterly sales data of all single and combination antimicrobial medicines. For our data extract IQVIA aggregated the data across hospital and community sectors and captured sales by generic and nongeneric manufacturers; the data do not distinguish between indication or patient characteristics. IQVIA data are routinely used to understand sales volumes of pharmaceuticals and to conduct international comparisons. More details on the data set are provided in the author’s data repository.

To extract data on systemic antibiotic formulations from the sales database, we developed a comprehensive list of antibiotics used in human medicine. We used three sources: (i) WHO list of critically important antimicrobials for human medicine, 2018 edition; (ii) WHO anatomical therapeutic chemical (ATC) code J01 (antibacterials for systemic use); and (iii) WHO AWaRe classification, as presented in the 2019 WHO essential medicines list and in the WHO AWaRe classification database. Included antibiotics were those defined as antibacterials for systemic use; we excluded antifungal and antiviral drugs, drugs solely for tuberculosis and topical formulations. We reviewed the full IQVIA database to identify any potentially missed or non-classified systemic antibiotics; national data were reviewed by country experts.

Data analysis

We estimated sales volumes in standard units (SU). SU refers to the number of standard dose units sold, where a dose is defined by IQVIA as one tablet or capsule for solid forms, one ampoule or vial for injectable forms, and 5 mL for syrup forms. We aggregated data at the year level by country and product. We defined each antibiotic product as...
Access, Watch, Reserve or Not Recommended, according to the 2019 AWaRe categorization. As the classification did not include all antibiotics identified in the sales data, we created a fifth group – unclassified – containing all systemic antibiotics not listed. We determined antibiotic pharmacological classifications using a combination of WHO ATC third- and fourth-level groups. Products and related AWaRe and antibiotic classifications are listed in the data repository.

We used several metrics to explore sales patterns (Table 2). First, we calculated total antibiotic sales and antibiotic sales per person in each country, overall and by AWaRe category. We estimated per capita sales by linking total sales to total annual population estimates from the World Bank. Second, we calculated the percentage sales of each AWaRe category. Percentages were calculated as the number of SU's of antibiotics in each group divided by the total number of antibiotic SU's sold. The percentage of Access group antibiotics sold was described relative to the 60% target. We assessed sales trends between 2013 and 2018 using simple linear regression by country and overall. Overall trends were estimated using the population-weighted aggregate mean sales across all eight countries (details in the data repository). Next, we examined sales of specific antibiotic pharmacological classes, presenting the data as proportions of total antibiotic sales and proportions of the specific AWaRe category sale. Finally, to explore country-specific prescribing habits, we identified all products contributing to at least 3% of country-specific consumption in 2018 and all products for which one country contributed more than 60% of total consumption across our sample.

We compiled additional data to analyse between-country differences in antibiotic sales. Country-level sociodemographic indicators were obtained from the World Bank. We obtained information on each country's implementation of national antimicrobial policies from national reports and the WHO library of national action plans. Lastly, to validate the results, we compared country–year findings against European consumption data from the European Surveillance of Antimicrobial Consumption Network (see the data repository). We analysed all data using Stata, version 14.2 (StataCorp, College Station, USA).

**Results**

As of May 2020, all countries had implemented an antimicrobial national action plan and three countries had adopted AWaRe for antibiotic use surveillance (Germany, Switzerland and the United Kingdom; Table 3). France implemented a similar categorization in 2013, before AWaRe was published. In 2018, the median annual sales of systemic antibiotics were 1.1 billion SU, ranging from 0.1 billion in Switzerland to 6.0 billion in the USA. We found variability among the countries in 2018 levels of sales per capita, from the lowest in Germany and Switzerland (7.4 and 9.3 SU per capita, respectively) to the highest in France, Spain, the United Kingdom and USA (20.0, 18.2, 19.6 and 18.4 SU per capita, respectively). Overall antibiotic sales declined moderately between 2013 and 2018, both in terms of total sales and sales per capita (Fig. 1; Fig. 2; Fig. 3; Fig. 4). In 2018, the median sales of Access group antibiotics were 10.9 SU per capita (range: 3.5–15.0) and median sales of antibiotics in the Watch group were 4.4 SU per capita (range: 2.2–12.3). In 2018, the median percentage of Access group antibiotics sold was 68.3%, varying from 21.6% (439/2030 million SU) of total sales in Japan to 76.8% in the United Kingdom (1000/1302 million SU) and 77.2% in the USA (4649/6020 million SU; Table 4; Fig. 1). When evaluated against the 60% target, five of the eight countries (France, Spain, Switzerland, the United Kingdom and USA) exceeded the 60% threshold and two were within 5.0 percentage points (Germany and Italy: 57.5% and 56.3%, respectively); only Japan's figure was substantially lower. The percentage of Access group antibiotics sold increased over 2013–2018 in all countries by a population-

| Outcome | Level of analysis | Definition |
|---------|-------------------|------------|
| Total annual sales, SU | Overall | Total sales of systemic antibiotics per year in SU |
| Annual sales per capita, SU per capita | Overall, by AWaRe category and by pharmacological class | No. of SU sold per year divided by the country–year population estimate derived from the World Bank |
| Relative sales, % of total sales | By AWaRe category and by pharmacological class | No. of SU sold in each group divided by the total no. of antibiotic SU sold in the given year (multiplied by 100) |
| Relative sales, % of AWaRe category sales | By pharmacological class | No. of SU sold of the specific antibiotic class and AWaRe category divided by the no. of AWaRe category SU sold in the given year (multiplied by 100) |
| ≥ 3% sales indicator | By individual antibiotic | Products accounting for ≥ 3% of country-specific consumption in 2018. Calculated as the no. of SU sold of each antibiotic divided by the total no. of SU by country in 2018 |
| Single country indicator, ≥60% of total sales | By individual antibiotic | Products accounting for ≥ 60% of per capita consumption. Calculated as the no. of per capita SU sold for a particular antibiotic in each country divided by the total per capita SU over all countries in 2018. Calculated for all products identified in the ≥ 3% consumption list |

**Table 2. Outcome definitions used in the study of antibiotic sales in eight high-income countries**

AWaRe: Access, Watch and Reserve classification; SU: standard units.

Note: The unit for all analyses was the country–year level. We identified AWaRe antibiotic categories according to the World Health Organization 2019 classification. We categorized pharmacological class according to the WHO anatomical therapeutic chemical third and fourth levels (see the data repository for classifications).
weighted average annual change of 0.9 percentage points (P < 0.001; Table 4; Fig. 5). Variation arose mainly between the Access and Watch groups, with sales of these categories accounting for a median of 98.8% of sales (range: 97.3–99.7). Reserve group antibiotics made up less than 1.5% of sales in all countries and years (median in 2018: 0.4%; range: 0.2–1.2). Not Recommended and unclassified products accounted for a small proportion of total sales (median in 2018: 0.5%; range: 0.1–2.2).

Sales by pharmacological class and AWaRe category are shown in the data repository.23 Access group penicillins accounted for a median 70.7% (range: 47.6–86.6) of Access group antibiotics sold in 2018 and 48.8% (range: 13.9–64.2) of total antibiotic sales. The sales pattern of Access group penicillin varied between countries, with most classified as extended-spectrum penicillins (median: 31.8% of Access group; range: 19.3–52.0) or extended-spectrum with β-lactamase inhibitor (median: 22.0% of Access group; range: 8.8–67.0). The United Kingdom had a higher use of narrow-spectrum β-lactamase-sensitive and -resistant penicillins at 27.4% (357/1302 million SU) of total sales. Japan had lower relative sales of Access group penicillins than other countries at 13.9% (283/2030 million SU) of total sales. Sulfonamides were the second most sold Access group antibiotic (median: 8.0% of Access group; range: 3.3–15.0; 4.0% of total; range: 2.2–7.9) followed by tetracyclines (median: 7.2% of Access group; range: 2.0–13.8; 5.2% of total; range: 1.1–10.7). The most frequently sold Watch group antibiotics were cephalosporins (median: 24.9% of Watch group; range: 2.0–43.2; 6.8% of total; range: 0.4–33.3), fluoroquinolones (median 24.6% of Watch group; range: 10.5–42.5; 8.9% of total; range: 2.3–12.6), and macrolides (median: 25.4% of Watch group; range: 17.2–42.2; 6.7% of total; range: 5.2–23.8). In Japan, Watch cephalosporins sold more than in other countries both in terms of percentage of Watch group antibiotics (43.2%; 675/1562 million SU) and overall antibiotic sales (33.3%; 675/2030 million SU), driven by high sales of third-generation cephalosporins. The most widely sold Reserve group antibiotics were polymyxins (median: 47.8% of Reserve group; range: 3.1–72.0) and oxazolidinones (median: 20.5% of Reserve group; range: 2.7–45.3); these made up a very small proportion of overall sales (<0.5%).

Amoxicillin was the only product that accounted for ≥3% of sales in all countries assessed (median: 19.0% of total consumption; range: 10.0–34.0; 2.8 SU per capita); amoxicillin/clavulanic acid sales were ≥3% in all countries except Japan (median 14.4%; range: 1.9–37.7; 2.0 SU per capita) as shown in the data repository.23 In total, nine products were sold primarily in one country (defined as one country accounting for ≥60% of total consumption); three were sold exclusively in one country: pristinamycin (France), cefcapene pivoxil (Japan) and oxytetracycline (the United Kingdom).

For external validity, we compared comparable country–year results against European Centre for Disease Prevention and Control network data for France, Italy, Spain and the United Kingdom. These results showed a strong correlation and support the validity of our results (see the data repository).23

Discussion
It is encouraging that in 2018 several of the countries studied achieved the WHO 60% Access group target, with a median percentage sales of Access group antibiotics across the eight countries of 68%. Of the three countries not meeting the target, Italy and Germany narrowly missed it, while Japan’s proportion was notably lower. Most countries made progress in optimizing antibiotic sales between 2013 and 2018, both in terms of an increase in the relative sales of Access group products and a decrease in per person sales of antibiotics.

Table 3. Country characteristics and antibiotic policies

| Variable                        | France | Germany | Italy | Japan | Spain | Switzerland | United Kingdom | United States |
|---------------------------------|--------|---------|-------|-------|-------|-------------|----------------|--------------|
| Sociodemographic characteristics|        |         |       |       |       |             |                 |              |
| WHO Region                      | Europe | Europe  | Europe| Western Pacific | Europe | Europe | Europe | Americas |
| Population, total in millions   | 67.0   | 82.9    | 60.4  | 126.5 | 46.7  | 8.5        | 66.5           | 327.2        |
| GDP per capita, PPP current thousands of international dollars | 45.9 | 54.3 | 42.1 | 43.3 | 40.9 | 68.9 | 46.2 | 62.6 |
| Health expenditure per capita, PPP current thousands of international dollars | 5.3 | 6.1 | 3.6 | 4.5 | 3.6 | 8.1 | 4.6 | 10.6 |
| Health expenditure, % of GDP    | 11.2   | 11.2    | 8.8   | 10.9  | 8.9   | 12.2       | 9.8            | 16.9         |
| Antibiotic policies             |        |         |       |       |       |             |                 |              |
| National action plan on antibiotic use | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Adopted AWaRe categorization in national policy | No, use similar categorization | Yes | No | No | No | Yes | Yes, adapted | No |

AWaRe: Access, Watch and Reserve classification; GDP: gross domestic product; PPP: purchasing power parity; WHO: World Health Organization.

Note: Data shown are from the most recent year available between 2013 and 2018.
The AWaRe classification and associated target provides a framework for simplified and standardized antibiotic surveillance and has the support of the G20 group of governments and central bank governors. Some of the studied countries have already adopted AWaRe for surveillance of antibiotics in an effort to translate international guidance into effective stewardship. To most effectively inform practice, England and Scotland in the United Kingdom have adapted the index to their local context, re-categorizing certain products, based on local resistance profiles, antibiotic use and the health-care setting. Preceding AWaRe, France initiated a similar categorization with associated targets and incentivized quality improvement mechanisms.

In 2018, WHO released the first global report applying the 2017 AWaRe classification to evaluate 2015 levels of antibiotic use. We build upon this report and other studies, using the updated 2019 AWaRe categorization and more recent data through to 2018, and providing a detailed analysis of specific consumption patterns. In comparison with these studies, we observed marginally higher relative sales of Access group antibiotics, while the intra-country differences and time
trends remained similar. Our analysis highlights cross-country differences in per capita antibiotic sales. For example, consistent with other reports, Germany and Switzerland sold relatively small quantities of antibiotics. Across countries, most heterogeneity was observed between Access and Watch group antibiotics; sales of Reserve category and Not Recommended products were low. Cross-country comparisons allow for some inferences about the appropriateness of antibiotic sales but should be interpreted with caution due to differences in burden, resistance profiles, treatment guidelines and health systems.

Japan stands out as having a differing pattern of antibiotic consumption. We found lower relative sales of Access group broad-spectrum penicillins and higher sales of Watch category antibiotics, predominantly driven by high relative sales of third-generation cephalosporins and, to a lesser extent, macrolides and fluoroquinolones. These findings corroborate other studies of antimicrobial sales in Japan. The differences in sales patterns have several potential explanations. Many of the products sold in Japan were of Japanese origin and some products were rarely sold in other countries. This pattern might suggest a difference in regulatory
requirements that discourage Japanese companies from seeking market authorization outside of Asia and likewise delaying or preventing uptake of products of non-Japanese origin. Japanese authorities may also prefer marketing strategies focusing on the domestic market.\textsuperscript{37,38} Differences in resistance patterns, patient demographics and cultural factors might also contribute to a different uptake of products in Japan. The Japanese antimicrobial national action plan promotes optimization of drug use and targets a reduced consumption of cephalosporins, fluoroquinolones and macrolides by 50% in 2020 from the 2013 baseline level.\textsuperscript{39} We observed progress towards this target with around 15% reduction of cephalosporin, fluoroquinolone and macrolide sales, but further action is required to meet targets.

The 60% Access group target provides a simple metric to monitor Access and promote responsible antibiotic use, but an emphasis on relative consumption alone could have unintended consequences on absolute consumption. In Germany, the Access group target was narrowly missed. The target could be achieved by a switch from second-generation Watch group cephalosporins to the Access group first-generation cephalosporins, but likewise it could be met through unnecessarily increasing sales of Access group products. Japan, despite a low Access group index, had relatively low total antibiotic sales and relatively low reported rates of antibiotic resistance. The European Centre for Disease Prevention and Control list of indicators for monitoring antibiotic consumption utilizes an absolute measure as the primary indicator of consumption to consider the amount of antimicrobials used.\textsuperscript{40} Secondary indicators, such as the ratio of broad-spectrum to narrow-spectrum antibiotics, overlap largely with the AWaRe Watch and Reserve group categories. Our findings and complementary assessment tools illustrate the importance for future stewardship policies in combining the Access group target with measures of total absolute consumption to give a more nuanced view of antibiotic stewardship.

Our study had some limitations. We estimated sales using SU, a standardized measure within the data source representing a single dose unit of sales. This method differs from the WHO...
consumption surveillance, which uses the ATC/defined daily dose method of calculation. SU provide an easily interpretable and standardized measure that does not require assumptions of sales which may not be correct in all settings and case-mixes of patients. However, the use of SU may limit comparisons across populations, particularly when dosing regimens and durations are variable, possibly biasing results towards the sales of antibiotics with longer durations or frequencies of dosing. As in previous studies, we observed a strong correlation between defined daily doses and SU when comparing our results with European Surveillance of Antibiotic Consumption Network data for European countries. Our findings show similar trends to the WHO report and other recent studies.

The use of sales data has certain limitations. Foremost, we did not study individual-level consumption. We could not determine patient characteristics and indications for treatment: factors critical to determining the appropriateness of prescribing and antibiotic use. Second, sales data may not be representative of the entire market – particularly for those countries where the data covers less than 100% of the pharmaceutical market – and the IQVIA algorithm to produce nationally representative estimates is not publicly available. Third, it may not be possible to disaggregate data by sector, facility and subnational geographies. Finally, the use of aggregate sales data provides a simple and standardized proxy for antibiotic consumption but should be complemented by analysis of data sources that enable conclusions to be drawn about the appropriateness of antibiotic use at the patient level. Future studies should assess consumption using sources such as prescribing data, dispensing records, and insurance and reimbursement records. Indicators using these data could more closely reflect the quality of antimicrobial prescribing.

Finally, while including a smaller subset of countries has allowed for a more in-depth analysis of antibiotic sales practices in this selection of highly developed countries, the findings need to be complemented by global data and more heterogeneous settings. Global increases in antibiotic consumption have been shown to be driven by rapid increases in consumption of Watch group antibiotics, particularly in low- and
middle-income countries, highlighting the need for broader analyses to support stewardship efforts. In addition, future analyses could more deeply explore factors associated with differences in sales, how AWaRe is being adopted and adapted to national contexts and stewardship plans, and the impact of the introduction of AWaRe on antibiotic sales and resistance patterns. Monitoring antibiotic consumption is an essential policy action highlighting potential areas where changes are needed to reduce the risk of antimicrobial resistance. As countries adopt the WHO AWaRe framework, there is a need to assess changes in antibiotic sales and use over time, and whether the WHO Access target is sufficient to preserve antibiotic efficacy across a range of infections or should be expanded. All countries should consider adapting the AWaRe classification and target to individual settings, with country-specific targets unambiguously reported in antimicrobial national action plans. Additional metrics, such as those focusing on absolute consumption, and more ambitious targets are needed to better adapt appropriateness of antibiotic use, particularly in mature health-care systems.

■

Acknowledgements
We thank colleagues on the WHO Expert Committee on the Selection and Use of Essential Medicines. MM and GC contributed equally to the manuscript.

Funding: GC is supported in part by the Imperial College NHS Biomedical Research Centre and an NIHR Professorship. BS was supported in part by MSF and UNITAID.

Competing interests: None declared.
高收入国家实现抗生素使用目标的进展

目的 旨在根据 2019 年世界卫生组织（WHO）可用、慎用和备用（AWaRe）分级原则和 60% 可用级抗生素消费目标，比较 8 个高收入国家的抗生素销售情况。

方法 我们分析了 2013 至 2018 年期间德国、法国、美国、日本、瑞士、西班牙、意大利和英国全国性抗生素销售相关商业数据库的数据。根据 2019 年 AWaRe 分级原则对抗生素进行了分级：可用级、慎用级和不推荐使用。我们基于人均标准单位 (SU) 推算了人头抗生素销售额，并计算了可用级抗生素销售额占抗生素总销售额的百分比。

结果 2018 年，人均抗生素销售额为 7.4 SU（瑞士）至 20.0 SU（法国）不等；可用级抗生素的平均销售额为 10.9 SU（范围：3.5–15.0）。2013–2018 年间人均销售额有所下降。可用级抗生素的中位百分比为 68%（范围：22–77%）；2013 年至 2018 年间，大多数国家的可用级抗生素消费比例有所上升。有 5 个国家超过 60% 的消费目标；两个国家非常接近该目标值（德国和意大利均大于 55%）。鉴于其口服头孢菌素和大环内酯类药物销售额相对较高，日本的可用级抗生素的销售额较低（22%）。

结论 我们已确定处方更改方案，以帮助各国实现世卫组织的目标。60% 可用级抗生素消费目标为国家制定抗生素政策提供了框架，同时可针对特定环境设定一些绝对控制措施和宣扬更加着眼于未来的价值观。

Résumé

Progress accompli en matière de consommation d'antibiotiques dans huit pays à hauts revenus

Objectif Comparer les ventes d'antibiotiques dans huit pays à hauts revenus à l'aide de la classification AWaRe (Access, Watch et Reserve) mise en place en 2019 par l'Organisation mondiale de la Santé, ainsi que de l'objectif de consommation de 60% fixé pour les antibiotiques de la catégorie Access.

Méthodes Nous avons analysé les informations issues d'une base de données commerciales concernant la vente d'antibiotiques systématiques entre 2013 et 2018 en Allemagne, en Espagne, aux États-Unis d'Amérique, en France, en Italie, au Japon, au Royaume-Uni de Grande-Bretagne et d'Irlande du Sud et en Suisse. Nous avons réparti ces antibiotiques selon les catégories AWaRe 2019: Access (antibiotiques dont l'accessibilité est essentielle), Watch (antibiotiques à utiliser sélectivement) et Reserve (antibiotiques de réserve, non recommandés). Nous avons mesuré les ventes d'antibiotiques en unités standard (SU) par habitant, et calculé celles de la catégorie Access sous forme de pourcentage des ventes totales.

Résultats En 2018, les ventes d'antibiotiques par habitant étaient comprises entre 7.4 SU (Suisse) et 20.0 SU (France); la valeur médiane des ventes d'antibiotiques Access s'élevait à 10.9 SU par habitant (écart: 3.5-15.0); les ventes par habitant ont diminué modérément au fil des ans entre 2013 et 2018. Le pourcentage médian des antibiotiques Access était de 68% (écart: 22–77%); dans la plupart des pays, leur pourcentage a augmenté entre 2013 et 2018. Cinq pays dépassaient l'objectif de 60%; deux autres s'en approchaient (> 55% en Allemagne et en Italie). La vente d'antibiotiques Access au Japon était faible (22%) en raison d'une forte consommation de macrolides et de céphalosporines orales.

Conclusion Nous avons constaté une évolution dans les prescriptions, ce qui pourrait permettre aux pays d'atteindre l'objectif de l'OMS. Une limite de consommation d'antibiotiques Access fixée à 60% pourrait servir d'orientation aux politiques nationales en la matière, et être complétée par des mesures absolues et des chiffres plus ambitieux dans des contextes spécifiques.
Resumen

Avances hacia los objetivos de uso de antibióticos en ocho países con ingresos altos

Objetivo Comparar las ventas de antibióticos en ocho países con ingresos altos utilizando la clasificación de acceso, vigilancia y reserva (AWaRe) de la Organización Mundial de la Salud (OMS) de 2019 y el objetivo de consumo del 60% de los antibióticos de la categoría de acceso.

Métodos Analizamos los datos de una base de datos comercial de ventas de antibióticos sistémicos en Francia, Italia, Japón, Alemania, España, Suiza, Reino Unido de Gran Bretaña e Irlanda del Norte y Estados Unidos de América durante los años 2013-2018. Clasificamos los antibióticos según las categorías AWaRe de 2019: acceso, vigilancia, reserva y no recomendado. Medimos las ventas de antibióticos per cápita en unidades estándar (SU) per cápita y calculamos las ventas del grupo de acceso como porcentaje de las ventas totales de antibióticos.

Resultados En 2018, las ventas per cápita de antibióticos oscilaron entre 7,4 SU (Suiza) y 20,0 SU (Francia); la media de las ventas de antibióticos del grupo de acceso fue de 10,9 SU per cápita (rango: 3,5-15,0). Las ventas per cápita disminuyeron moderadamente durante 2013-2018. La media del porcentaje de antibióticos del grupo de acceso fue del 68% (rango: 22-77%); la proporción del grupo de acceso aumentó en la mayoría de los países entre 2013 y 2018. Cinco países superaron el objetivo del 60%; dos países lo incumplieron por un escaso margen (> 55% en Alemania e Italia). Las ventas de antibióticos de acceso en Japón fueron bajas (22%), impulsadas por una venta relativamente alta de cefalosporinas orales y macróldidos.

Conclusión Hemos identificado cambios en la prescripción que podrían permitir a los países alcanzar el objetivo de la OMS. El objetivo del 60% del grupo de acceso proporciona un marco para informar las políticas nacionales de antibióticos y podría complementarse con medidas absolutas y valores más ambiciosos en entornos específicos.

Referencias

1. Antimicrobial resistance: global report on surveillance. Geneva: World Health Organization, 2014. Available from: https://www.who.int/drugresistance/documents/surveillancereport/en/ [cited 2019 Aug 8].

2. Laxminarayan R, Amábile-Cuevas CF, Cars O, Evans T, Heymann DL, Hoffman S, et al. UN High-Level Meeting on antimicrobials — what do we need? Lancet. 2016 Jul 16;388(10041):218–20. doi: http://dx.doi.org/10.1016/S0140-6736(16)31079-0 PMID: 27479554

3. Laxminarayan R, Duse A, Wartell C, Zadik AK, Wertheim HF, Supradit N, et al. Antibiotic resistance — the need for global solutions. Lancet Infect Dis. 2013 Dec;13(12):1057–98. doi: http://dx.doi.org/10.1016/S1473-3099(13)70318-9 PMID: 24524883

4. Global action plan on antimicrobial resistance. Geneva: World Health Organization, 2015. Available from: https://www.who.int/antimicrobial -resistance/publications/global-action-plan/en/ [cited 2019 Aug 8].

5. Sharland M, Pulcini C, Harbarth S, Zeng M, Gandra S, Mathur S, et al.; 21st WHO Expert Committee on Selection and Use of Essential Medicines. Classifying antibiotics in the WHO Essential Medicines List for optimal use — be AWaRe. Lancet Infect Dis. 2018 Jan;18(1):18–20. doi: http://dx.doi.org/10.1016/S1473-3099(17)30274-7 PMID: 29203731

6. The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization, 2017. Available from: https://www.who.int/medicines/publications/essentialmedicines/trs-1006-2017/en/ [cited 2019 Aug 6].

7. AWaRe policy brief. Geneva: World Health Organization, 2019. Available from: https://apps.who.int/iris/handle/10665/239757 [cited 2019 Oct 2].

8. The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization, 2019. Available from: https://www.who.int/medicines/publications/essentialmedicines/en/ [cited 2020 Jan 15].

9. In the face of slow progress, WHO offers a new tool and sets a target to accelerate action against antimicrobial resistance. Geneva: World Health Organization, 2019.

10. Sharland M, Gandra S, Huttner B, Moja L, Pulcini C, Zeng M, et al.; EML Expert Committee and Antibiotic Working Group. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use—the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. Lancet Infect Dis. 2019 Dec;19(12):1278–80. doi: http://dx.doi.org/10.1016/S1473-3099(19)30532-8 PMID: 31782385

11. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Genfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014 Aug;14(8):742–50. doi: http://dx.doi.org/10.1016/S1473-3099(14)07080-7 PMID: 25022435

12. Versporten A, Zarb P, Caniaux J, Gros MF, Draper N, Miller M, et al.; Global-PSS network. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health. 2018 Jun;6(6):e19–29. doi: http://dx.doi.org/10.1016/S2214-109X(18)30166-4 PMID: 29681513

13. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018 Apr 10;115(15):E3463–70. doi: http://dx.doi.org/10.1073/pnas.1712795115 PMID: 29581252

14. Jackson C, Hsia Y, Belickey JA, Ellis S, Stephens P, Wong ICK, et al. Estimating global trends in total and childhood antibiotic consumption, 2011–2015. BMJ Glob Health. 2019 Feb 27;4(1):e001241. doi: http://dx.doi.org/10.1136/bmjgh-2018-001241 PMID: 30899565

15. Klein EY, Milkowska-Shibata M, Tieng KK, Sharland M, Gandra, Pulcini, et al. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data. Lancet Infect Dis. 2020; doi: http://dx.doi.org/10.1016/S1473-3099(20)30332-7 PMID: 32712705

16. Hsia Y, Lee BR, Versporten A, Yang Y, Belickey J, Jackson C, et al. GARPEC and Global-PSS networks. Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries. Lancet Glob Health. 2019 Jul 7;7(7):e861–71. doi: http://dx.doi.org/10.1016/S2214-109X(19)30071-3 PMID: 31200888

17. Hsia Y, Sharland M, Jackson C, Wong ICK, Magrini N, Belickey JA. Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries. Lancet Infect Dis. 2019 Jan;19(1):67–75. doi: http://dx.doi.org/10.1016/S1473-3099(18)30547-4 PMID: 30522834

18. WHO report on surveillance of antibiotic consumption. 2016–2018 early implementation. Geneva: World Health Organization, 2018. Available from: https://apps.who.int/iris/handle/10665/277359 [cited 2020 Dec 19].

19. The 2019 WHO AWaRe classification of antibiotics for evaluation and monitoring of use (WHO/essential medicines list/AIU/2019.11). Geneva: World Health Organization, 2019. Available from: https://www.who.int/medicines/news/2019/WHO_releases2019AWaRe_classification _antibiotics/en/ [cited 2020 Jan 20].

20. Cook MN. Estimating national drug consumption using data at different points in the pharmaceutical supply chain. Pharmacoepidemiol Drug Saf. 2006 Oct;15(10):754–7. doi: http://dx.doi.org/10.1002/pds.16989003

21. MIDAS* [Internet]. Durham: QVIA, 2021. Available from: https://www.qvia.com/solutions/commercialization/brand-strategy-and-management/ market-monitoring/mdis [cited 2021 Apr 8].

Bryony Simmons et al.
Bull World Health Organ. 2021;99:550–561. doi: http://dx.doi.org/10.2471/BLT.20.270934

22. Klein EY, Tseng KK, Pant S, Laxminarayan R. Tracking global trends in the effectiveness of antibiotic therapy using the Drug Resistance Index. BMJ Glob Health. 2019 Apr 11;4(2):e001315. doi: http://dx.doi.org/10.1136/bmjgh-2018-001315 PMID: 3119449

23. Simmons B, Arroyo K, Ohmagari N, Pulcini C, Huttner B, Gandra S, et al. Supplementary webappendix: Progress towards WHO AWaRe targets [data repository]. London: figshare, 2019. doi: http://dx.doi.org/10.6084/m9.figshare.14384588

24. Kållberg C, Årdal C, Salvesen Blix H, Klein E, M Martinez E, Lindbæk M, et al. Introduction and geographic availability of new antibiotics approved between 1999 and 2014. PLoS One. 2018 Oct 16;13(10):e0205166. doi: http://dx.doi.org/10.1371/journal.pone.0205166 PMID: 30325963

25. Källberg C, Årdal C, Salvesen Blix H, Klein E, M Martinez E, Lindbæk M, et al. Characterization of antibiotics considered to be ‘critical’: first reflections on their characteristics (information point) [internet]. Saint-Denis Cedex: Agence nationale de sécurité du medicament; 2013. French. Available from: https://archiveansm.integra.fr/afssaps/S-informer/Points-d-information/Points-d-information/Points-d-information/Les-antibiotiques-considerees-comme-critiques-premieres-reflexions-sur-leur-caracterisation-Point-d-information [cited 2020 Mar 16].

26. Howard P, Huttner B, Beovic B, Beraud G, Koteridis DP, Pano Pardo J, et al.; ESGAP Indicators Working Group. ESGAP inventory of target indicators assessing antibiotic prescriptions: a cross-sectional survey. J Antimicrob Chemother. 2017 Oct 1;72(10):2910–4. doi: http://dx.doi.org/10.1093/jac/dkx243 PMID: 29091207

27. Antimicrobial consumption database (ESAC-Net) [internet]. Solna: European Centre for Disease Prevention and Control; 2019. Available from: https://www.ecdc.europa.eu/en/antimicrobial-consumption/surveillance-and-disease-data/database [cited 2019 Dec 10].

28. Adopt AWaRe: handle antibiotics with care. Geneva: World Health Organization; 2019. Available from: https://www.who.int/foodsafety/publications/antimicrobials-sixth/en/ [cited 2020 Jan 20].

29. Declaration. G20 Meeting of Health Ministers 2018, 4 October 2018, Mar del Plata, Argentina. Cancín: Group of 20, 2018. Available from: http://www.g20utoronto.ca/2018/2018-10-04-health.pdf [cited 2020 Jun 18].

30. Budd E, Cramp E, Sharland M, Hand K, Howard P, Wilson P, et al. Adoption of the WHO Essential Medicines List for national antibiotic stewardship policy in England: being AWaRe. J Antimicrob Chemother. 2019 Nov 1;74(11):3384–9. doi: http://dx.doi.org/10.1093/jac/dkz321 PMID: 31361000

31. Howard P, Huttner B, Beovic B, Beraud G, Koteridis DP, Pano Pardo J, et al.; AMOXDOSE working group. Amoxicillin dosing recommendations are very different in European countries: a cross-sectional survey. Clin Microbiol Infect. 2017 Jun;23(6):414–5. doi: http://dx.doi.org/10.1016/j.cmi.2016.11.013 PMID: 27890458

32. ECDC, EFSA Panel on Biological Hazards (BIOHAZ); EMA Committee for Medicinal Products for Veterinary Use (CVMP). ECDC, EFSA and EMA Joint Scientific Opinion on a list of outcome indicators as regards surveillance of antimicrobial resistance and antimicrobial consumption in humans and food-producing animals. EFSA J. 2017 10 26;15(10):e05017. PMID: 28648767

33. Galiano MM, Lenzzi J, Bonaudo M, Fantini MP, Ricciardi W, Damiani G. Predictors and trajectories of antibiotic consumption in 22 EU countries: Findings from a time series analysis (2000–2014). PLoS One. 2018 Jun 22;13(6):e0199436. doi: http://dx.doi.org/10.1371/journal.pone.0199436 PMID: 29933377

34. Pulcini C, Beovic B, Cavalie P, Deputa A, D’Oyar O, Gyssens I, et al.; ESGAP AMOXDOSE working group. Amoxicillin dosing recommendations are very different in European countries: a cross-sectional survey. Clin Microbiol Infect. 2017 Jun;23(6):414–5. doi: http://dx.doi.org/10.1016/j.cmi.2016.11.013 PMID: 27890458

35. Tsutsui A, Yahara K, Shibayama K. Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. J Infect Chemother. 2018 Jun;24(6):414–21. doi: http://dx.doi.org/10.1016/j.jiac.2018.01.003 PMID: 29428566

36. Tsuji K, Tsutani K. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations. J Clin Pharm Ther. 2010 Jun;35(3):289–301. doi: http://dx.doi.org/10.1111/j.1365-2710.2009.01099.x PMID: 20848767

37. Howard P, Huttner B, Beovic B, Beraud G, Koteridis DP, Pano Pardo J, et al.; ESGAP Indicators Working Group. ESGAP inventory of target indicators assessing antibiotic prescriptions: a cross-sectional survey. J Antimicrob Chemother. 2017 Oct 1;72(10):2910–4. doi: http://dx.doi.org/10.1093/jac/dkx243 PMID: 29091207

38. Tsuji K, Tsutani K. Approval of new drugs: 1999–2007. Comparison of the US, the EU and Japan situations. J Clin Pharm Ther. 2010 Jun;35(3):289–301. doi: http://dx.doi.org/10.1111/j.1365-2710.2009.01099.x PMID: 20848767

39. Tsutsui A, Yahara K, Shibayama K. Trends and patterns of national antimicrobial consumption surveillance: first report on oral and parenteral antimicrobial consumption in Japan (2009–2013). J Glob Antimicrob Resist. 2016 Dec;7:19–23. doi: http://dx.doi.org/10.1016/j.jgar.2016.07.002 PMID: 27973324

40. ECDC, EFSA Panel on Biological Hazards (BIOHAZ); EMA Committee for Medicinal Products for Veterinary Use (CVMP). ECDC, EFSA and EMA Joint Scientific Opinion on a list of outcome indicators as regards surveillance of antimicrobial resistance and antimicrobial consumption in humans and food-producing animals. EFSA J. 2017 10 26;15(10):e05017. PMID: 32625307

41. Patel S, Jhass A, Hopkins S, Shallcross L. Informing the development of a standardised approach to measure antibiotic use in secondary care: a systematic review protocol. BMJ Open. 2019 May 14(5):e026792. doi: http://dx.doi.org/10.1136/bmjopen-2018-026792 PMID: 31092658